Compare ADMA Biologics Inc (ADMA) vs Teradyne, Inc. (TER) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Teradyne, Inc. — how do they compare? ADMA Biologics Inc trades at $9.19 (market cap $2.13B), while Teradyne, Inc. trades at $342.12 (market cap $53.71B). The key difference: Teradyne, Inc. is far larger — about 25.2× ADMA Biologics Inc's market cap, and Teradyne, Inc. pays a 0.15% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | TER | |
|---|---|---|
Market Cap | $2.13B | $53.71B |
Sector | Health | Technology |
52-Week High | $20.38 | $483.84 |
52-Week Low | $7.60 | $90.15 |
Enterprise Value | $2.20B | $53.55B |
Dividend Yield | — | 0.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Teradyne (TER) trades at $343.11, down 7.04% amid a semiconductor sector sell-off, yet maintains strong fundamentals with 22.55% net margins and consistent earnings beats. The stock shows bearish technical signals but benefits from robust AI-driven demand, with 64.5% analyst buy ratings and a $453.60 consensus target suggesting 32% upside. Recent dividend declaration and strong cash flow generation support long-term stability despite near-term volatility.
Outlook remains positive given Teradyne's leadership in semiconductor testing and robotics, with AI infrastructure spending driving growth. Risks include sector cyclicality and premium valuations (P/E 70.4), but earnings momentum and institutional support provide cushion. The stock presents a compelling opportunity for investors seeking AI infrastructure exposure with proven execution capabilities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
